The joint venture in which Halberd is leading, as it has the license for the Felder-patents, is about developing an extracorporeal treatment for the safe removal of targeted antigens from the blood and targeted organs. It's about developing a treatment against all sorts of diseases, but COVID-19 makes it possible to get the funding they need to make it happen. But don't take my word for it, follow the news and especially about the funding of the $2 million "technology acquisition and financing agreement", a large part of it being realised by now. After that they need at least another $25 million for clinical trials, and they will get it because there's unlimited funding available. And HALB will not be shut down by the SEC because their academic partner is the University of Texas at El Paso and UTEP is the partner that did the same clinical work in cooperation with JV-partner BIEI in the past. When BIEI ran out of cash before they could finish their clinical work, the results based on the Felder-patents was put aside and they tried to set up their CBD-business. They came up with some of the best products in the market but their marketing sucked and everything else sucked as well. With new funding we're back to where it all started and this time they may succeed. If they do they will hit the jackpot, they have all patents related to this extracorporeal treatment. And then there's the anti-addiction patch, fully covered with another 2 patents. If they get funding (and I think they will) it's party time here very soon.
JMO (do your own DD)
News 
Market Data 
Discover 
